Clinical trial · Observational
Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )
NCT02603315CI-TRIAL-00022439VITMPMcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Mesotheliomas | Malignant Mesothelioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| marker CD74 and vascular endothelial growth factor VEGF | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival
- timeFrame
- 3-4 months
- description
- The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment
Secondary outcomes (1)
- measure
- assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74
- timeFrame
- 3-4 months
- description
- The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 39 Years
- Maximum age
- 84 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathological confirmation of malignant pleural mesothelioma . * Full clinical data. * Availability for follow up: Personal communication will be attempted in order to collect missing information. 3-The files of all patients will be reviewed to analyze the following : * Operative data if done . * Pathological review and immunohistochemistry. * Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test) * Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\\S and MRI ). * Treatment protocols applied: Radiotherapy and Chemotherapy. * Response and survival after treatment . Exclusion Criteria: * cases not receive chemotherapy ,on available of evaluation after treatment
References
Publications (0)
Data not yet available
No reference posted for this study.